Press Release

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Lupin appoints Jim Loerop as Chief Corporate Development Officer

Mumbai, September 18, 2017: Pharma Major Lupin announced the appointment of Jim Loerop as Chief Corporate Development Officer. Jim will lead Lupin's overall corporate development efforts and will be responsible for the Company's global M&A and business development functions. He will integrate Lupin's Business development, Licensing and M&A teams to drive the company's global M&A and Business Development strategy.

A seasoned professional with over 27 years of experience in the pharmaceutical industry, Jim joins Lupin from Alexion Pharmaceuticals, Inc. where he served as Senior Vice President of Global Business Development. Prior to Alexion, he held multiple leadership positions at leading pharmaceutical companies such as GlaxoSmithKline, Stiefel (a GSK Company), KV Pharmaceutical and Curatek Pharmaceuticals. Jim graduated from Western Michigan University with a major in Marketing following which he began his career as a Sales Representative with Solvay Pharmaceuticals.

Commenting on the appointment, Vinita Gupta, Chief Executive Officer, Lupin said, *"We are delighted to welcome Jim at a crucial time as we accelerate our transition into complex generics and specialty brand segments. Jim's rich experience in both branded and generic business will be invaluable in helping us navigate our business towards new growth opportunities."*

Jim will be based at Naples, Florida in the US, and he will report to Vinita Gupta, CEO, Lupin.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Paediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 7th and 6th largest generics pharmaceutical company by market capitalization (June 30th, 2017, Bloomberg) and revenues (March 31st, 2017, Bloomberg) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); 2nd largest Indian pharmaceutical company by global revenues (March 31st, 2017, Bloomberg); 6th largest generic pharmaceutical player in Japan and 6th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT June 2017).

For the financial year ended 31st March, 2017, Lupin's Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter - www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications

Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPC IN

Lupin Limited
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Or

Arvind Bothra
Head – Investor Relations and M&A
Lupin Limited
Email: arvindbothra@lupin.com
Ph: +91-22-66402137